温馨提示：本站仅提供公开网络链接索引服务，不存储、不篡改任何第三方内容，所有内容版权归原作者所有
AI智能索引来源：http://www.prnewswire.com/news-releases/health-latest-news/international-medical-approval-list
点击访问原文链接

All International Medical Approval News and Press Releases from PR Newswire

进入原网站 导航首页
Accessibility StatementResourcesInvestor RelationsJournalistsAgenciesClient LoginSend a ReleaseNewsProductsContactBrowse News ReleasesAll News ReleasesAll Public CompanyEnglish-onlyNews Releases OverviewMultimedia GalleryAll MultimediaAll PhotosAll VideosMultimedia Gallery OverviewTrending TopicsAll Trending TopicsAuto & TransportationAll Automotive & TransportationAerospace, DefenseAir FreightAirlines & AviationAutomotiveMaritime & ShipbuildingRailroads and Intermodal TransportationSupply Chain/LogisticsTransportation, Trucking & RailroadTravelTrucking and Road TransportationAuto & Transportation OverviewView All Auto & TransportationBusiness TechnologyAll Business TechnologyBlockchainBroadcast TechComputer & ElectronicsComputer HardwareComputer SoftwareData AnalyticsElectronic CommerceElectronic ComponentsElectronic Design AutomationFinancial TechnologyHigh Tech SecurityInternet TechnologyNanotechnologyNetworksPeripheralsSemiconductorsBusiness Technology OverviewView All Business TechnologyEntertain­ment & MediaAll Entertain­ment & MediaAdvertisingArtBooksEntertainmentFilm and Motion PictureMagazinesMusicPublishing & Information ServicesRadio & PodcastTelevisionEntertain­ment & Media OverviewView All Entertain­ment & MediaFinancial Services & InvestingAll Financial Services & InvestingAccounting News & IssuesAcquisitions, Mergers and TakeoversBanking & Financial ServicesBankruptcyBond & Stock RatingsConference Call AnnouncementsContractsCryptocurrencyDividendsEarningsEarnings Forecasts & ProjectionsFinancing AgreementsInsuranceInvestments OpinionsJoint VenturesMutual FundsPrivate PlacementReal EstateRestructuring & RecapitalizationSales ReportsShareholder ActivismShareholder MeetingsStock OfferingStock SplitVenture CapitalFinancial Services & Investing OverviewView All Financial Services & InvestingGeneral BusinessAll General BusinessAwardsCommercial Real EstateCorporate ExpansionEarningsEnvironmental, Social and Governance (ESG)Human Resource & Workforce ManagementLicensingNew Products & ServicesObituariesOutsourcing BusinessesOverseas Real Estate (non-US)Personnel AnnouncementsReal Estate TransactionsResidential Real EstateSmall Business ServicesSocially Responsible InvestingSurveys, Polls and ResearchTrade Show NewsGeneral Business OverviewView All General BusinessConsumer TechnologyAll Consumer TechnologyArtificial IntelligenceBlockchainCloud Computing/Internet of ThingsComputer ElectronicsComputer HardwareComputer SoftwareConsumer ElectronicsCryptocurrencyData AnalyticsElectronic CommerceElectronic GamingFinancial TechnologyMobile EntertainmentMultimedia & InternetPeripheralsSocial MediaSTEM (Science, Tech, Engineering, Math)Supply Chain/LogisticsWireless CommunicationsConsumer Technology OverviewView All Consumer TechnologyEnergy & Natural ResourcesAll EnergyAlternative EnergiesChemicalElectrical UtilitiesGasGeneral ManufacturingMiningMining & MetalsOil & EnergyOil and Gas DiscoveriesUtilitiesWater UtilitiesEnergy & Natural Resources OverviewView All Energy & Natural ResourcesEnviron­mentAll Environ­mentConservation & RecyclingEnvironmental IssuesEnvironmental PolicyEnvironmental Products & ServicesGreen TechnologyNatural DisastersEnviron­ment OverviewView All Environ­mentHeavy Industry & ManufacturingAll Heavy Industry & ManufacturingAerospace & DefenseAgricultureChemicalConstruction & BuildingGeneral ManufacturingHVAC (Heating, Ventilation and Air-Conditioning)MachineryMachine Tools, Metalworking and MetallurgyMiningMining & MetalsPaper, Forest Products & ContainersPrecious MetalsTextilesTobaccoHeavy Industry & Manufacturing OverviewView All Heavy Industry & ManufacturingTelecomm­unicationsAll Telecomm­unicationsCarriers and ServicesMobile EntertainmentNetworksPeripheralsTelecommunications EquipmentTelecommunications IndustryVoIP (Voice over Internet Protocol)Wireless CommunicationsTelecomm­unications OverviewView All Telecomm­unicationsConsumer Products & RetailAll Consumer Products & RetailAnimals & PetsBeers, Wines and SpiritsBeveragesBridal ServicesCannabisCosmetics and Personal CareFashionFood & BeveragesFurniture and FurnishingsHome ImprovementHousehold, Consumer & CosmeticsHousehold ProductsJewelryNon-Alcoholic BeveragesOffice ProductsOrganic FoodProduct RecallsRestaurantsRetailSupermarketsToysConsumer Products & Retail OverviewView All Consumer Products & RetailEntertain­ment & MediaAll Entertain­ment & MediaAdvertisingArtBooksEntertainmentFilm and Motion PictureMagazinesMusicPublishing & Information ServicesRadio & PodcastTelevisionEntertain­ment & Media OverviewView All Entertain­ment & MediaHealthAll HealthBiometricsBiotechnologyClinical Trials & Medical DiscoveriesDentistryFDA ApprovalFitness/WellnessHealth Care & HospitalsHealth InsuranceInfection ControlInternational Medical ApprovalMedical EquipmentMedical PharmaceuticalsMental HealthPharmaceuticalsSupplementary MedicineHealth OverviewView All HealthSportsAll SportsGeneral SportsOutdoors, Camping & HikingSporting EventsSports Equipment & AccessoriesSports OverviewView All SportsTravelAll TravelAmusement Parks and Tourist AttractionsGambling & CasinosHotels and ResortsLeisure & TourismOutdoors, Camping & HikingPassenger AviationTravel IndustryTravel OverviewView All TravelPolicy & Public InterestAll Policy & Public InterestAdvocacy Group OpinionAnimal WelfareCongressional & Presidential CampaignsCorporate Social ResponsibilityDomestic PolicyEconomic News, Trends, AnalysisEducationEnvironmentalEuropean GovernmentFDA ApprovalFederal and State LegislationFederal Executive Branch & AgencyForeign Policy & International AffairsHomeland SecurityLabor & UnionLegal IssuesNatural DisastersNot For ProfitPatent LawPublic SafetyTrade PolicyU.S. State PolicyPolicy & Public Interest OverviewView All Policy & Public InterestPeople & CultureAll People & CultureAboriginal, First Nations & Native AmericanAfrican AmericanAsian AmericanChildrenDiversity, Equity & InclusionHispanicLesbian, Gay & BisexualMen's InterestPeople with DisabilitiesReligionSenior CitizensVeteransWomenPeople & Culture OverviewView All People & CultureArabicespañolportuguêsČeskoDanmarkDeutschlandEspañaFranceItaliaNederlandNorgePolskaPortugalРоссияSlovenskoSuomiSverigeExplore Our PlatformPlan CampaignsCreate with AIDistribute Press ReleasesAmplify ContentAll ProductsGeneral InquiriesEditorial BureausPartnershipsMedia InquiriesWorldwide OfficesSend a ReleaseALL CONTACT INFOContact UsSend a ReleaseClient LoginResourcesBlogJournalistsRSSBrowse All NewsMultimedia GalleryTrending TopicsAuto & TransportationBusiness TechnologyEntertain­ment & MediaFinancial Services & InvestingGeneral BusinessConsumer TechnologyEnergy & Natural ResourcesEnviron­mentHeavy Industry & ManufacturingTelecomm­unicationsConsumer Products & RetailEntertain­ment & MediaHealthSportsTravelPeople & CultureSend a ReleaseClient LoginResourcesBlogJournalistsRSSExplore Our PlatformPlan CampaignsCreate with AIDistribute Press ReleasesAmplify ContentAll ProductsSend a ReleaseClient LoginResourcesBlogJournalistsRSSGeneral InquiriesEditorial BureausPartnershipsMedia InquiriesWorldwide OfficesSend a ReleaseClient LoginResourcesBlogJournalistsRSSMar 30, 2026, 08:20 ET 4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union 4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging software, announces that its latest imaging technology, CT:VQ™ has received...Mar 30, 2026, 02:20 ET 4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union 4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging software, announces that its latest imaging technology, CT:VQ™ has received...Mar 30, 2026, 02:20 ET 4DMedical erhält CE-Kennzeichnung für CT:VQ™ und ermöglicht damit die Markteinführung in der gesamten Europäischen Union 4DMedical Limited (ASX:4DX), der weltweit führende Anbieter von Software für die kardiothorakale Bildgebung, gibt bekannt, dass seine neueste...Mar 30, 2026, 02:20 ET Avec l'obtention du marquage CE pour CT:VQ™, 4DMedical est prêt pour sa mise sur le marché dans l'Union européenne 4DMedical Limited (ASX:4DX), le leader mondial des logiciels d'imagerie cardiothoracique, annonce que sa dernière technologie d'imagerie, CT:VQ™, a...Mar 30, 2026, 02:20 ET 4DMedical recibe la marca CE para CT:VQ™, lo que permitirá su lanzamiento comercial en toda la Unión Europea 4DMedical Limited (ASX:4DX), el líder mundial en software de imágenes cardiotorácicas, anuncia que su última tecnología de imágenes, CT:VQ™, ha...Mar 26, 2026, 02:23 ET GC Biopharma Receives Marketing Authorization for Varicella Vaccine 'BARYCELA Inj.' in Guatemala GC Biopharma(006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that its varicella vaccine, BARYCELA Inj.,...Mar 23, 2026, 06:59 ET Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved...Mar 15, 2026, 22:05 ET Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R),...Mar 12, 2026, 08:30 ET Baird Medical Expands Global Reach with Regulatory Clearance in Argentina Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation...Mar 09, 2026, 04:32 ET Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in...Mar 06, 2026, 08:48 ET LifeVac Becomes the First and Only FDA-Authorized Anti-Choking Device LifeVac LLC announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo classification for LifeVac under 21 CFR 874.5400,...Mar 05, 2026, 08:39 ET HealthTech Bridge Launches to Accelerate Clinical Validation and U.S. Market Readiness for International HealthTech Innovators HTA and Venture Atlas Labs announced a new commercial and clinical acceleration program that connects international health technology companies with...Mar 03, 2026, 05:46 ET Asieris' CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions Asieris Pharmaceuticals (Stock Code: 688176.SH), a global innovative pharmaceutical company focused on genitourinary tumors and women's health,...Mar 03, 2026, 00:48 ET Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) ...Mar 01, 2026, 19:00 ET Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes...Feb 27, 2026, 07:01 ET Norgine celebra la opinión positiva del CHMP que recomienda la aprobación de mavorixafor Norgine B.V., empresa farmacéutica especializada líder en Europa, acoge hoy con satisfacción la opinión positiva emitida por el Comité de...Feb 27, 2026, 07:01 ET Norgine begrüßt positive CHMP-Stellungnahme, die die Zulassung von Mavorixafor in der Europäischen Union für das WHIM-Syndrom empfiehlt Norgine B.V., ein führendes europäisches Spezialpharmaunternehmen, begrüßt heute die positive Stellungnahme des Ausschusses für Humanarzneimittel...Feb 27, 2026, 07:01 ET Norgine se félicite de l'avis positif du CHMP recommandant l'approbation du mavorixafor dans l'Union européenne pour le syndrome WHIM Norgine B.V., une société pharmaceutique européenne spécialisée de premier plan, se félicite aujourd'hui de l'avis positif émis par le Comité des...Feb 27, 2026, 07:01 ET Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome Norgine B.V., a leading European specialty pharmaceutical company, today welcomes the positive opinion issued by the European Medicines Agency's...Feb 27, 2026, 07:01 ET Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome Norgine B.V., a leading European specialty pharmaceutical company, today welcomes the positive opinion issued by the European Medicines Agency's...Feb 24, 2026, 08:37 ET HYDRINITY Accelerated Skin Science Expands into France HYDRINITY Accelerated Skin Science, the fastest-growing professional skincare brand in the U.S., is pleased to announce a new strategic partnership...Feb 22, 2026, 04:51 ET Lenire muestra resultados positivos consistentes para pacientes con tinnitus en Estados Unidos La revista American Journal of Audiology ha revisado y publicado los resultados positivos obtenidos en pacientes estadounidenses con tinnitus...Feb 19, 2026, 13:25 ET Une première mondiale en soins néonatals : le Japon approuve les fortifiants 100 % à base de lait humain de Prolacta Bioscience en tant que médicament sur ordonnance pour les nourissons vulnérables Prolacta Bioscience® annonce aujourd'hui que le ministère japonais de la Santé, du Travail et des Affaires sociales (MHLW) vient d'approuver la...Feb 19, 2026, 13:23 ET Eine Weltneuheit in der Neugeborenenpflege: Japan genehmigt die zu 100 % aus Muttermilch hergestellten Nahrungsergänzungsmittel von Prolacta Bioscience als verschreibungspflichtiges Medikament für gefährdete Säuglinge. Prolacta Bioscience® hat heute bekannt gegeben, dass das japanische Ministerium für Gesundheit, Arbeit und Soziales (MHLW) PreemieFort® Enteral...Feb 19, 2026, 08:14 ET SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that Nevisense...GET STARTEDPR Newswire for JournalistsSubmit a free ProfNet requestLEARN MOREGeneral InquiriesEditorial BureausPartnershipsMedia InquiriesWorldwide OfficesFor MarketersFor Public RelationsFor IR & ComplianceFor AgencyAll ProductsAbout PR NewswireAbout CisionBecome a Publishing PartnerBecome a Channel PartnerCareersAccessibility StatementAPACAPAC - Simplified ChineseAPAC - Traditional ChineseBrazilCanadaCzechDenmarkFinlandFranceGermanyIndiaIndonesiaIsraelItalyJapanKoreaMexicoMiddle EastMiddle East - ArabicNetherlandsNorwayPolandPortugalRussiaSlovakiaSpainSwedenUnited KingdomVietnamAll New ReleasesPlatform LoginProfNetData PrivacyDo not sell or share my personal information[email protected]Contact PR NewswireProductsAboutAll News ReleasesPlatform LoginProfNetTerms of UsePrivacy PolicyInformation Security PolicySite MapRSSCookiesCision

智能索引记录